Welcome to our dedicated page for Ambiq Micro news (Ticker: AMBQ), a resource for investors and traders seeking the latest updates and insights on Ambiq Micro stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ambiq Micro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ambiq Micro's position in the market.
Ambiq (NYSE:AMBQ) has released neuralSPOT SDK V1.2.0 Beta, enhancing AI development support for its Apollo510 and Apollo510B systems-on-chips. The update features HeliaRT Beta integration, delivering up to 3X faster inference and improved energy efficiency compared to LiteRT implementations.
The SDK includes a comprehensive example library with ready-to-deploy models for various applications including human activity recognition, ECG monitoring, and keyword spotting. The Apollo510, which won the Best Hardware Award at Embedded World 2024, powers the heartKIT™ AI SDK, which received the Best AI Solutions Award at Embedded World 2025.
Ambiq (NYSE:AMBQ) reported its Q2 2025 financial results, with net sales increasing 13.6% sequentially to $17.9 million. The company recently completed an upsized IPO, raising $97.2 million through the sale of 4.6 million shares at $24.00 per share.
Q2 2025 highlights include a gross profit of $7.2 million (40.1% margin) and a net loss of $8.5 million ($18.89 per share). The company successfully reduced its China exposure to 11.5% of sales, down from 42.0% year-over-year, as part of its strategic geographic diversification.
For Q3 2025, Ambiq expects net sales between $17.5-18.0 million and projects a non-GAAP loss per share of ($0.35) to ($0.28).
Ambiq (NYSE:AMBQ) has announced the expansion of its Apollo5 Family with the launch of the Apollo510B wireless System-on-Chip (SoC). The new chip integrates a dedicated 48MHz network processor and Bluetooth Low Energy 5.4 radio, designed specifically for power-constrained edge AI applications.
The Apollo510B features the Arm Cortex-M55 processor with Helium and turboSPOT technology, delivering up to 30x better power efficiency in AI applications and 16x faster performance over Cortex-M4 devices. The chip includes enhanced memory architecture, advanced GPU capabilities, and comprehensive peripheral support, making it ideal for wearables, smart glasses, remote patient monitoring, and industrial automation applications.
Ambiq Micro (NYSE: AMBQ), a leader in ultra-low-power semiconductor solutions for edge AI, has scheduled its Q2 2025 financial results announcement for September 4, 2025, after market close.
CEO Fumihide Esaka and CFO Jeff Winzeler will host a conference call at 3:30 PM CT (4:30 PM ET). The call will be accessible via phone and webcast, with replay options available until September 11, 2025.
Ambiq (NYSE:AMBQ), a leader in ultra-low-power semiconductor solutions for edge AI, has successfully completed its upsized Initial Public Offering (IPO). The company sold 4.6 million shares at $24.00 per share, which includes the full exercise of the underwriters' option to purchase 600,000 additional shares.
The IPO generated gross proceeds of $110.4 million before deducting underwriting discounts and other expenses. Trading of Ambiq shares commenced on the New York Stock Exchange on July 30, 2025, under the ticker symbol "AMBQ". BofA Securities and UBS Investment Bank served as joint lead book-running managers, with Needham & Company and Stifel acting as joint book-running managers.